Maintenance of vertebral body bone mass and strength created by human parathyroid hormone treatment in ovariectomized rats.

Samnegård E, Akhter MP, Recker RR

Bone1 Apr 2001Cited by 9 (Europe PMC)

PMID11336923DOI10.1016/s8756-3282(01)00408-2PepBankPUB-11336923

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, hPTH restored vertebral BMD to intact rat levels.
In plain wordsIn rats, hPTH restored spine bone density to levels in rats with intact ovaries.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseVertebral BMD restoration
Study
ratn: not reported in source
ovariectomized rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
75 microg/kg per day, 3 days/week · subcutaneous · 12 weeksAs given in this study (rat).
Source sentences
Summary
The hPTH treatment for 12 weeks restored BMD to the level of intact rats.
1 context sentence(design, population, supporting numbers)
Summary · context
For the following 12 weeks, four ovx groups received subcutaneous injections of hPTH (75 microg/kg per day, 3 days/week) and four groups received vehicle.
Report a problemFND-1133692301
02AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, hPTH increased vertebral ultimate stress (p = 0.02).
In plain wordsIn rats, hPTH increased the stress that spine bone could withstand.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseVertebral ultimate stress
Study
ratn: not reported in source
ovariectomized rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
75 microg/kg per day, 3 days/week · subcutaneous · 12 weeksAs given in this study (rat).
Source sentences
Summary
Ultstr and ModUS followed a similar pattern, but the ovx-induced Ultstr was not significant (p = 0.073, ModUS: p = 0.003), nor was the hPTH-induced increase in ModUS (p = 0.131, Ultstr: p = 0.02).
1 context sentence(design, population, supporting numbers)
Summary · context
For the following 12 weeks, four ovx groups received subcutaneous injections of hPTH (75 microg/kg per day, 3 days/week) and four groups received vehicle.
Report a problemFND-1133692302
03AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, hPTH increased ultrasound modulus without statistical significance (p = 0.131).
In plain wordsIn rats, hPTH increased the ultrasound stiffness measure, but the result was not statistically significant.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseUltrasound modulus
Study
ratn: not reported in source
ovariectomized rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
75 microg/kg per day, 3 days/week · subcutaneous · 12 weeksAs given in this study (rat).
Source sentences
Summary
Ultstr and ModUS followed a similar pattern, but the ovx-induced Ultstr was not significant (p = 0.073, ModUS: p = 0.003), nor was the hPTH-induced increase in ModUS (p = 0.131, Ultstr: p = 0.02).
1 context sentence(design, population, supporting numbers)
Summary · context
For the following 12 weeks, four ovx groups received subcutaneous injections of hPTH (75 microg/kg per day, 3 days/week) and four groups received vehicle.
Report a problemFND-1133692303
04AnimalAnimal study (in vivo)Efficacy outcome
After hPTH withdrawal, vertebral BMD in rats did not differ from ovariectomized animals.
In plain wordsIn rats after hPTH withdrawal, spine bone density did not differ from animals with ovaries removed.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
No significant changeBMD after withdrawal
Study
ratn: not reported in source
ovariectomized rats
Comparator
ovariectomized animals
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
After hPTH withdrawal, BMD, Ultstr, and ModUS levels were not different from levels in ovx animals.
Report a problemFND-1133692304
05AnimalAnimal study (in vivo)Efficacy outcome
After hPTH withdrawal, rat vertebral ultimate stress did not differ from ovariectomized animals.
In plain wordsIn rats after hPTH withdrawal, spine bone strength did not differ from animals with ovaries removed.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
No significant changeUltimate stress after withdrawal
Study
ratn: not reported in source
ovariectomized rats
Comparator
ovariectomized animals
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
After hPTH withdrawal, BMD, Ultstr, and ModUS levels were not different from levels in ovx animals.
Report a problemFND-1133692305
06AnimalAnimal study (in vivo)Efficacy outcome
After hPTH withdrawal, rat vertebral ultrasound modulus did not differ from ovariectomized animals.
In plain wordsIn rats after hPTH withdrawal, spine ultrasound stiffness did not differ from animals with ovaries removed.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
No significant changeUltrasound modulus after withdrawal
Study
ratn: not reported in source
ovariectomized rats
Comparator
ovariectomized animals
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
After hPTH withdrawal, BMD, Ultstr, and ModUS levels were not different from levels in ovx animals.
Report a problemFND-1133692306
07AnimalAnimal study (in vivo)Efficacy outcome
In hPTH-pretreated rats, low-dose hPTH increased BMD versus ovariectomized animals at weeks 24 and 48 (p < 0.001).
In plain wordsIn rats previously given hPTH, low-dose hPTH increased spine bone density versus animals with ovaries removed.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseMaintenance BMD
Study
ratn: not reported in source
ovariectomized rats
Comparator
ovariectomized animals
Outcome group
Bone and joint · Musculoskeletal
Studied dose
25 microg/kg per day, 3 days/week · 36 weeksAs given in this study (rat).
Source sentences
Summary
In LowPTH-treated rats pretreated with hPTH, BMD (weeks 24 and 48, p < 0.001) and Ultstr (week 48, p = 0.005) were greater than in ovx animals.
1 context sentence(design, population, supporting numbers)
Summary · context
Treatments were then changed to: E2 (10 microg/kg per day, 2 days/week); Ris (3 microg/kg per day, 3 days/week); LowPTH (25 microg/kg per day, 3 days/week); or vehicle for 36 weeks.
Report a problemFND-1133692307
08AnimalAnimal study (in vivo)Efficacy outcome
In hPTH-pretreated rats, low-dose hPTH increased ultimate stress versus ovariectomized animals at week 48 (p = 0.005).
In plain wordsIn rats previously given hPTH, low-dose hPTH increased spine bone strength versus animals with ovaries removed.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseMaintenance ultimate stress
Study
ratn: not reported in source
ovariectomized rats
Comparator
ovariectomized animals
Outcome group
Bone and joint · Musculoskeletal
Studied dose
25 microg/kg per day, 3 days/week · 36 weeksAs given in this study (rat).
Source sentences
Summary
In LowPTH-treated rats pretreated with hPTH, BMD (weeks 24 and 48, p < 0.001) and Ultstr (week 48, p = 0.005) were greater than in ovx animals.
1 context sentence(design, population, supporting numbers)
Summary · context
Treatments were then changed to: E2 (10 microg/kg per day, 2 days/week); Ris (3 microg/kg per day, 3 days/week); LowPTH (25 microg/kg per day, 3 days/week); or vehicle for 36 weeks.
Report a problemFND-1133692308

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.